DNA prime and virus-like particle boost from a single H5N1 strain elicits broadly neutralizing antibody responses against head region of H5 hemagglutinin

Journal of Infectious Diseases

Volumn 209, Issue 5, 2014, Pages 676-685

  Wang, Guiqin ^a   Zhou, Fan ^a   Buchy, Philippe ^b   Zuo, Teng ^c   Hu, Hongxing ^a   Liu, Jingjing ^a   Song, Yufeng ^a   Ding, Heng ^a   Tsai, Cheguo ^a   Chen, Ze ^d   Zhang, Linqi ^c   Deubel, Vincent ^b   Zhou, Paul ^a  

^a INSTITUTE PASTEUR OF SHANGHAI   (China)

^b INSTITUT PASTEUR DU CAMBODGE   (Cambodia)

^c Tsinghua University   (China)

^d Shanghai Institute of Biological Products   (China)

Author keywords

HPAI H5N1; neutralizing antibody responses; vaccination

Indexed keywords

HPAI H5N1; NEUTRALIZING ANTIBODY RESPONSES; VACCINATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; VACCINATION; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84894233437     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit414     Document Type: Conference Paper

References (50)

1. United Nations Food and Agriculture Organization. FAO ECTAD HPAI situation update. No.562. Food and Agriculture Organization. New York. 2013.
2. World Health Organization. H5N1 avian influenza: timeline of major events. Geneva, Switzerland: WHO, 2013.
3. Watanabe Y, Ibrahim MS, Ellakany HF, et al. Acquisition of humantype receptor binding specificity by new H5N1 influenza virus sublineages during their emergence in birds in Egypt. PLoS Pathog 2011; 7: e1002068.
4. Herfst S, Schrauwen EJ, Linster M, et al. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 2012; 336:1534-41.
5. Imai M, Watanabe T, Hatta M, et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 2012; 486:420-8.
6. Neumann G, Macken CA, Karasin AI, Fouchier RA, Kawaoka Y. Egyptian H5N1 influenza viruses-cause for concern? PLoS Pathog 2012; 8: e1002932.
7. WHO/OIE/FAO H5N1 Evolution Working Group. Continued evolution of highly pathogenic avian influenza A (H5N1): updated nomenclature. Influenza Other Respi Viruses 2012; 6:1-5.
8. World Health Organization. Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness. Geneva, Switzerland: WHO, 2013.
9. Bright RA, Carter DM, Crevar CJ, et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 2008; 3:e1501.
10. Crevar CJ, Ross TM. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine. Virol J 2008; 5:131.
11. Rao S, Kong WP, Wei CJ, et al. Multivalent HA DNA vaccination protects against highly pathogenic H5N1 avian influenza infection in chickens and mice. PLoS One 2008; 3:e2432.
12. Forrest HL, Khalenkov AM, Govorkova EA, Kim JK, Del Giudice G, Webster RG. Single-and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets. Vaccine 2009; 27:4187-95.
13. Tao P, Luo M, Zhu D, et al. Virus-like particle vaccine comprised of the HA, NA, and M1 proteins of an avian isolated H5N1 influenza virus induces protective immunity against homologous and heterologous strains in mice. Viral Immunol 2009; 22:273-81.
14. Chen MW, Cheng TJ, Huang Y, et al. A consensus-hemagglutininbased DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc Natl Acad Sci USA 2008; 105:13538-43.
15. Ducatez MF, Bahl J, Griffin Y, et al. Feasibility of reconstructed ancestral H5N1 influenza viruses for cross-clade protective vaccine development. Proc Natl Acad Sci USA 2011; 108:349-54.
16. Gaschen B, Taylor J, Yusim K, et al. Diversity considerations in HIV-1 vaccine selection. Science 2002; 296:2354-60.
17. Hu H, Voss J, Zhang G, et al. A human antibody recognizing a conserved epitope of H5 hemagglutinin broadly neutralizes highly pathogenic avian influenza H5N1 viruses. J Virol 2012; 86:2978-89.
18. Zhou F, Wang G, Buchy P, et al. A triclade DNA vaccine designed on the basis of a comprehensive serologic study elicits neutralizing antibody responses against all clades and subclades of highly pathogenic avian influenza H5N1 viruses. J Virol 2012; 86:6970-8.
19. Oh HL, Akerstrom S, Shen S, et al. An antibody against a novel and conserved epitope in the hemagglutinin 1 subunit neutralizes numerous H5N1 influenza viruses. J Virol 2010; 84:8275-86.
20. Wei CJ, Boyington JC, McTamney PM, et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 2010; 329:1060-4.
21. Ledgerwood JE, Wei CJ, Hu Z, et al. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis 2011; 11:916-24.
22. Ding H, Tsai C, Gutierrez RA, et al. Superior neutralizing antibody response and protection in mice vaccinated with heterologous DNA prime and virus like particle boost against HPAI H5N1 virus. PLoS One 2011; 6:e16563.
23. Prabakaran M, He F, Meng T, et al. Neutralizing epitopes of influenza virus hemagglutinin: target for the development of a universal vaccine against H5N1 lineages. J Virol 2010; 84:11822-30.
24. Prabakaran M, Kolpe AB, He F, Kwang J. Cross-protective efficacy of bivalent recombinant baculoviral vaccine against heterologous influenza H5N1 challenge. Vaccine 2013; 31:1385-92.
25. Okuno Y, Isegawa Y, Sasao F, Ueda S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 1993; 67:2552-8.
26. Throsby M, van den Brink E, Jongeneelen M, et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 2008; 3:e3942.
27. Ekiert DC, Bhabha G, Elsliger MA, et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009; 324:246-51.
28. Sui J, Hwang WC, Perez S, et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza Aviruses. Nat Struct Mol Biol 2009; 16:265-73.
29. Corti D, Voss J, Gamblin SJ, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011; 333:850-6.
30. Dreyfus C, Laursen NS, Kwaks T, et al. Highly conserved protective epitopes on influenza B viruses. Science 2012; 337:1314-8.
31. Wang TT, Tan GS, Hai R, et al. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog 2010; 6:e1000796.
32. Ekiert DC, Friesen RH, Bhabha G, et al. A highly conserved neutralizing epitope on group 2 influenza Aviruses. Science 2011; 333:843-50.
33. Bommakanti G, Citron MP, Hepler RW, et al. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc Natl Acad Sci USA 2010; 107: 13701-6.
34. Steel J, Lowen AC, Wang TT, et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 2010; 1. doi:10.1128/mBio.00018-10.
35. Wang TT, Tan GS, Hai R, et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci USA 2010; 107:18979-84.
36. Bommakanti G, Lu X, Citron MP, et al. Design of Escherichia coliexpressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge. J Virol 2012; 86:13434-44.
37. Chen Y, Qin K, Wu WL, et al. Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes. J Infect Dis 2009; 199:49-58.
38. Yoshida R, Igarashi M, Ozaki H, et al. Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza Aviruses. PLoS Pathog 2009; 5:e1000350.
39. Whittle JR, Zhang R, Khurana S, et al. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci USA 2011; 108:14216-21.
40. Ekiert DC, Kashyap AK, Steel J, et al. Cross-neutralization of influenza Aviruses mediated by a single antibody loop. Nature 2012; 489:6.
41. Lee PS, Yoshida R, Ekiert DC, et al. Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity. Proc Natl Acad Sci USA 2012; 109:17040-5.
42. Qian M, Hu H, Zuo T,Wang G, Zhang L, Zhou P. Unraveling of a neutralization mechanism by two human antibodies against conserved epitopes in the globular head of H5 hemagglutinin. J Virol 2013; 87:3571-7.
43. Simmons CP, Bernasconi NL, Suguitan AL, et al. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med 2007; 4:e178.
44. Khurana S, Wu J, Verma N, et al. H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. J Virol 2011; 85:10945-54.
45. Martin JE, Sullivan NJ, Enama ME, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 2006; 13:1267-77.
46. Martin JE, Louder MK, Holman LA, et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a phase I clinical trial. Vaccine 2008; 26: 6338-43.
47. Kibuuka H, Kimutai R, Maboko L, et al. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-uninfected East Africans (RV 172). J Infect Dis 2010; 201:600-7.
48. Ledgerwood JE, Pierson TC, Hubka SA, et al. AWest Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis 2011; 203:1396-404.
49. Lopez-Macias C, Ferat-Osorio E, Tenorio-Calvo A, et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine 2011; 29:7826-34.
50. Wei CJ, Yassine HM, McTamney PM, et al. Elicitation of broadly neutralizing influenza antibodies in animals with previous influenza exposure. Sci Transl Med 2012; 4:147ra14.